US Patent 5,545,403: Claim Scope, Validity Exposure, and US Landscape
US Patent 5,545,403 centers on a method of treating disease in humans with whole glycosylated recombinant human chimeric / CDR-grafted / bispecific antibodies, where the glycosylation is produced in a Chinese hamster ovary (CHO) cell. The independent claim is written broadly as a method-of-treatment formulation tied to an antibody attribute (CHO-derived glycosylation) rather than to a specific disease indication or a specific antibody sequence.
What do the claims actually require?
1) What is the core novelty hook?
Claim 1 requires all of the following elements:
- A method of treating a human suffering from a disease or disorder
- Administering a therapeutically effective amount of an antibody with these characteristics:
- Whole glycosylated
- Recombinant
- Human chimeric OR CDR-grafted OR bispecific
- Effective in treating the disease/disorder
- The improvement is specifically:
- “an antibody glycosylated by a chinese hamster ovary cell”
So the claimed “improvement” is not a new target per se; it is the glycosylation provenance (CHO) paired with a class of recombinant human chimeric/CDR-grafted/bispecific antibodies.
2) What do the dependent claims narrow?
Claims 2 and 3 add target specificity:
- Claim 2: antibody specifically binds CD4
- Claim 3: antibody specifically binds CDw52
Claims 4-7 add engineering format and species mapping for those target subsets:
- Claim 4: claim 2 + antibody is CDR-grafted
- Claim 5: claim 3 + antibody is CDR-grafted
- Claim 6: claim 2 + antibody is chimeric
- Claim 7: claim 3 + antibody is chimeric
Critically, dependent claims do not add any particular CDR sequences, epitope definition, glycan structures (beyond being CHO-derived), or assay readouts. They mostly restrict to target and format.
Claim-by-claim structure (as written)
| Claim |
Antibody format |
Target |
Added glycosylation requirement |
| 1 |
chimeric OR CDR-grafted OR bispecific |
any (disease/disorder is generic) |
whole glycosylated and CHO-glycosylated |
| 2 |
any of claim 1 formats |
CD4 |
CHO-glycosylated |
| 3 |
any of claim 1 formats |
CDw52 |
CHO-glycosylated |
| 4 |
CDR-grafted |
CD4 |
CHO-glycosylated |
| 5 |
CDR-grafted |
CDw52 |
CHO-glycosylated |
| 6 |
chimeric |
CD4 |
CHO-glycosylated |
| 7 |
chimeric |
CDw52 |
CHO-glycosylated |
Claim construction and practical scope
Is “CHO cell glycosylated” a structural limitation or a process limitation?
The claim ties glycosylation state to “glycosylated by a Chinese hamster ovary cell.” In practice, this tends to function as a product-by-process-style limitation: you must have a glycosylated antibody that reflects CHO processing.
However, the claim language does not explicitly recite:
- exact glycan species (e.g., afucosylation, sialylation patterns)
- enzymatic processing constraints (e.g., MGAT1 knockout, engineered CHO lines)
- glycan profiling methods
- molecular weight distributions or charge variants
That creates a risk that the “CHO-glycosylated” hook is treated as a broad provenance attribute rather than a reproducible structural feature that cleanly distinguishes from non-CHO glycoforms.
What antibodies are covered by “whole glycosylated recombinant human chimeric or CDR-grafted or bispecific”?
“Whole glycosylated” likely means glycosylated at the Fc and/or variable region where glycosylation exists on the antibody scaffold. But the claim does not specify:
- IgG subclass (human chimeric often points to IgG1/IgG2 scaffolds)
- whether glycosylation is required specifically at Fc N297
- whether variable-region glycosylation is required or just that the antibody is glycosylated overall
Because the claim’s scope is broad on antibody format and sequence, it can capture a wide set of recombinant antibody candidates so long as they meet:
- recombinant human chimeric or CDR-grafted or bispecific format
- functional binding to CD4 or CDw52 (for dependent claims)
- CHO-derived glycosylation
How broad is “disease or disorder”?
Claim 1 is written to cover treatment of any disease or disorder where a CHO-glycosylated antibody in the defined format is “effective.” That can be argued as a drafting strategy to avoid indication limits and instead rely on the specification’s examples to supply enablement and support.
The legal vulnerability is that “effective in treating said disease or disorder” can be interpreted broadly as a functional result, which can collide with novelty and obviousness if target-binding antibodies already existed and CHO expression was routine.
Patent landscape positioning: what this patent is trying to capture
The key targets named in dependent claims: CD4 and CDw52
CD4 is a well-established immunology target in HIV and autoimmune settings. CDw52 is associated with lymphocyte targeting, and antibodies against CDw52 have historically been positioned for hematologic conditions and immune modulation.
This makes the dependent claims important for landscape mapping: they attempt to lock in engineering format + CHO glycosylation for antibodies binding two named surface targets.
The “CHO glycosylation” angle appears as a general manufacturability hook
CHO is the dominant commercial mammalian expression platform for monoclonal antibodies. By anchoring the “improvement” to a CHO-derived glycosylation attribute, the patent attempts to convert an otherwise general manufacturing choice into a claim-limiting invention.
In competitive terms, the landscape implication is that this patent could be asserted against products whose glycosylation is consistent with standard CHO manufacturing, even if their claimed sequences and epitopes were developed elsewhere.
Critical validity and enforceability exposure
1) Obviousness risk: glycosylation by CHO was routine
If the prior art already taught recombinant human chimeric and CDR-grafted antibodies plus CHO-based expression, the “improvement” language may be viewed as routine optimization rather than a non-obvious technical advance.
Because dependent claims do not specify distinct glycan structures or engineered CHO lines, a challenge can argue:
- antibody engineering frameworks (chimeric, CDR-grafted) were known
- CHO expression for glycosylated Ig molecules was known
- therefore, the CHO glycosylation attribute did not supply a meaningful inventive step unless coupled to a specific functional glycan effect
2) Functional breadth: “effective in treating said disease or disorder”
Claim 1 is not anchored to a named indication or a concrete clinical endpoint. If the specification supports broad treatment contexts, the claim can survive written description and enablement only if the disclosure enables broad use without undue experimentation for each covered disease.
If the disclosure supports only limited disease examples, claim 1’s broad disease phrasing becomes vulnerable to:
- lack of adequate written description for the full breadth
- lack of enablement for all “diseases or disorders” not exemplified
3) Indefiniteness and product-by-process tension
“glycosylated by a chinese hamster ovary cell” can be attacked if it does not clearly define a reproducible characteristic that distinguishes the claimed antibody from alternatives. If accused products use non-CHO lines (e.g., HEK293, NS0) or use CHO lines with different engineered glycosylation profiles, the claim could be litigated on what “CHO-glycosylated” actually means in measurable terms.
At the same time, because CHO glycosylation can vary between lines and culture conditions, enforceability may depend on whether courts treat the limitation as:
- a strict process step requiring that the glycosylation was made in CHO, or
- a functional/provenance proxy not reliably mapped to end-product attributes
4) Infringement proof burden
For method-of-treatment claims, infringement typically requires proof that:
- the accused therapeutic is administered
- it contains the claimed antibody features
- its glycosylation reflects CHO-derived glycosylation consistent with the claim limitation
If the accused product is produced under contract manufacturing, with multilayered glycosylation controls, proving “glycosylated by CHO cell” may require manufacturing records, regulatory submissions, or analytical glycan profiling tied to CHO origin.
Landscape implications for businesses
Who would be most exposed?
- Companies with CD4-binding or CDw52-binding monoclonals whose glycosylation results from standard CHO expression.
- Programs using chimeric or CDR-grafted antibodies where glycosylation is not engineered into a distinct profile that could avoid the “CHO glycosylated” product-by-process hook.
Who can design around more easily?
- Programs that use non-CHO expression systems for producing the antibody (if feasible) to avoid the “glycosylated by CHO cell” limitation.
- Programs that use engineered glycosylation pathways and can establish that the product is not CHO-glycosylated in the sense required by the claim, depending on claim construction.
What matters for portfolio strategy
- This is a method claim. If a competitor sells an antibody for infusion, the litigation often focuses on whether the method claim is satisfied by prescribing/administering the product for an eligible disease.
- The patent attempts to keep indication broad. That can increase risk for a competitor with multiple indications where the antibody is “effective.”
Key takeaways
- US 5,545,403 claims a broad method-of-treatment using CHO-glycosylated recombinant human chimeric, CDR-grafted, or bispecific antibodies, with dependent claims narrowing to CD4 and CDw52 binding and to chimeric vs CDR-grafted formats.
- The inventive hook is framed around glycosylation provenance (CHO), but the claims do not recite specific glycan structures or engineered glycosylation characteristics, creating obviousness and enforceability vulnerabilities.
- For infringement and litigation strategy, the decisive technical question is not the antibody target alone; it is whether the accused product’s glycosylation is credibly shown to be CHO-cell glycosylated under the claim’s construction.
- For freedom-to-operate, the exposure concentrates on CD4/CDw52-directed antibodies produced in CHO and marketed for treatment contexts that can be mapped to “disease or disorder” supported by the patent.
FAQs
-
Does Claim 1 require a specific disease or indication?
No. It covers treatment of a “disease or disorder” as long as the CHO-glycosylated antibody is effective.
-
Do the dependent claims limit the glycosylation beyond CHO origin?
No. They refine format (CDR-grafted vs chimeric) and target (CD4 vs CDw52) but do not add specific glycan structures.
-
Is the “CHO glycosylated” limitation likely treated as process or product?
It functions like a provenance limitation tied to how the glycosylation was produced; in litigation, it can be treated similarly to product-by-process depending on claim construction.
-
What is the main technical differentiator in this patent?
The differentiator is the antibody being “whole glycosylated” and specifically “glycosylated by” CHO cells, rather than a novel target sequence or an engineered glycan motif.
-
Where is the highest litigation leverage likely to sit for competitors?
On whether prior art already made such antibodies with CHO expression and on whether the claimed CHO provenance is a meaningful structural distinction that can be proved for an accused product.
References
[1] United States Patent 5,545,403. Claims as provided in prompt.
